3-611: 2L9I , 2MNQ 5757 19231 ENSG00000187514 ENSMUSG00000026238 P06454 P26350 NM_001099285 NM_002823 NM_008972 NP_001092755 NP_002814 NP_032998 NP_001347759 NP_001347760 Thymosin α 1 is a peptide fragment derived from prothymosin alpha , a protein that in humans is encoded by the PTMA gene . It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Unlike β thymosins, to which it
6-635: Is approved in 35 under-developed or developing countries for the treatment of Hepatitis B and C , and it is also used to boost the immune response in the treatment of other diseases. Clinical trials suggest it may be useful in cystic fibrosis, septic shock , acute respiratory distress syndrome , peritonitis , acute cytomegalovirus infection , TB , severe acute respiratory syndrome , and lung infections in critically ill patients., and for chronic hepatitis B . It has been studied for possible use in treating cancer (e.g. with chemotherapy). Peptide fragment Too Many Requests If you report this error to
9-467: Is genetically and chemically unrelated, thymosin α 1 is produced as a 28-amino acid fragment, from a longer, 113-amino acid precursor, prothymosin α. Thymosin α 1 is believed to be a major component of Thymosin Fraction 5 responsible for the activity of that preparation in restoring immune function in animals lacking thymus glands. It has been found to enhance cell-mediated immunity in humans as well as experimental animals. As of 2009 Thymosin α 1
#456543